Morgan Stanley Call 300 PGR 20.12.../ DE000MG0BD76 /
02/08/2024 21:13:06 | Chg.-0.022 | Bid22:00:34 | Ask22:00:34 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.228EUR | -8.80% | - Bid Size: - |
- Ask Size: - |
Progressive Corporat... | 300.00 USD | 20/12/2024 | Call |
GlobeNewswire
25/06
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire
24/06
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Tri...
GlobeNewswire
24/06
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geo...
GlobeNewswire
24/06
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-4...
GlobeNewswire
13/06
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Progr...
GlobeNewswire
12/06
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo...
GlobeNewswire
12/06
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japa...
GlobeNewswire
11/06
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
11/06
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b...
GlobeNewswire
11/06
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclero...
GlobeNewswire
10/06
LifeWallet’s Proprietary Data System is Instrumental in Class Certification Against USAA Property an...